We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now?
Read MoreHide Full Article
Key Takeaways
CI is positioned for growth driven by new business and deeper client relationships at Evernorth.
CI's 2025 earnings estimate points to 8.4% growth, with revenues expected to rise over 10%.
CI returns capital through buybacks and dividends, supported by strong cash flow.
The Cigna Group (CI - Free Report) is well poised to grow on the back of new business and client relationship expansion in the Evernorth Health Services unit. Strategic focus shift, strong cash generating ability, shareholder value-boosting efforts and diversified and growing revenue streams are some major tailwinds.
Cigna — with a market cap of $74.6 billion — provides pharmacy services, benefits management, care solutions, health insurance products, as well as data and analytics. Courtesy of solid prospects, this Zacks Rank #3 (Hold) stock is worth holding on to at the moment.
Let’s delve deeper.
The Zacks Consensus Estimate for Cigna’s 2025 earnings is pegged at $29.63 per share, indicating a 8.4% year-over-year rise. It remained stable over the past 30 days. The company beat earnings estimates in three of the last four quarters and missed once.
The consensus estimate for 2025 revenues stands at $272.11 billion, suggesting a 10.1% rise. Expanding pharmacy benefit services, thanks to rising customers and prescription volumes and improving specialty volumes in Specialty and Care Services are expected to boost the top line. Its massive scale provides pricing power and unit economics. New client wins and renewed existing relationships help generate more service contract revenues.
Cigna has a strong shareholder value boosting program in place. In the first nine months of 2025, it repurchased a total of 8.2 million shares for $2.6 billion and paid dividends worth $1.2 billion. Over the past four reported quarters, it generated free cash flow of $7.4 billion.
Cigna trades at a forward P/E of 9.28X, well below its five-year median of 10.62X and the industry average of 15.84X. The discount suggests investors are focused on near-term uncertainties, potentially overlooking the company’s longer-term earnings power and structural growth drivers.
Key Concerns
There are a few factors that investors should keep an eye on.
Cigna’s return on assets of 5.01% is below the industry average of 5.65%, suggesting that the company is generating less profit from its assets relative to its industry peers. Its high debt level, with a net debt to capital of 35.68% (against the industry average of 24.04%), is a concern.
Also, a high MCR is affecting Cigna’s Healthcare profits. Nevertheless, we believe that a systematic and strategic plan of action will drive the company’s long-term growth.
The Zacks Consensus Estimate for CareDx’s current-year earnings implies a 25.5% increase from the year-ago reported figure. The consensus mark for its current-year revenues is pegged at $374.08 million. CDNA beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 76.5%.
The Zacks Consensus Estimate for Encompass Health’s 2025 earnings indicates a 19.6% year-over-year increase to $5.30 per share. It has witnessed one upward estimate revision over the past 60 days against no movement in the opposite direction. The consensus mark for EHC’s 2025 revenues indicates 10.4% growth from a year ago.
The Zacks Consensus Estimate for Ensign’s 2025 bottom line suggests 18.2% year-over-year growth. It beat earnings estimates in all the last four quarters, with an average surprise of 2.3%. ENSG has witnessed three upward estimate revisions over the past 60 days against no movement in the opposite direction.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now?
Key Takeaways
The Cigna Group (CI - Free Report) is well poised to grow on the back of new business and client relationship expansion in the Evernorth Health Services unit. Strategic focus shift, strong cash generating ability, shareholder value-boosting efforts and diversified and growing revenue streams are some major tailwinds.
Cigna — with a market cap of $74.6 billion — provides pharmacy services, benefits management, care solutions, health insurance products, as well as data and analytics. Courtesy of solid prospects, this Zacks Rank #3 (Hold) stock is worth holding on to at the moment.
Let’s delve deeper.
The Zacks Consensus Estimate for Cigna’s 2025 earnings is pegged at $29.63 per share, indicating a 8.4% year-over-year rise. It remained stable over the past 30 days. The company beat earnings estimates in three of the last four quarters and missed once.
Cigna Group Price, Consensus and EPS Surprise
Cigna Group price-consensus-eps-surprise-chart | Cigna Group Quote
The consensus estimate for 2025 revenues stands at $272.11 billion, suggesting a 10.1% rise. Expanding pharmacy benefit services, thanks to rising customers and prescription volumes and improving specialty volumes in Specialty and Care Services are expected to boost the top line. Its massive scale provides pricing power and unit economics. New client wins and renewed existing relationships help generate more service contract revenues.
Cigna has a strong shareholder value boosting program in place. In the first nine months of 2025, it repurchased a total of 8.2 million shares for $2.6 billion and paid dividends worth $1.2 billion. Over the past four reported quarters, it generated free cash flow of $7.4 billion.
Cigna trades at a forward P/E of 9.28X, well below its five-year median of 10.62X and the industry average of 15.84X. The discount suggests investors are focused on near-term uncertainties, potentially overlooking the company’s longer-term earnings power and structural growth drivers.
Key Concerns
There are a few factors that investors should keep an eye on.
Cigna’s return on assets of 5.01% is below the industry average of 5.65%, suggesting that the company is generating less profit from its assets relative to its industry peers. Its high debt level, with a net debt to capital of 35.68% (against the industry average of 24.04%), is a concern.
Also, a high MCR is affecting Cigna’s Healthcare profits. Nevertheless, we believe that a systematic and strategic plan of action will drive the company’s long-term growth.
Key Medical Picks
Some better-ranked stocks in the broader Medical space are CareDx, Inc. (CDNA - Free Report) , Encompass Health Corporation (EHC - Free Report) and The Ensign Group, Inc. (ENSG - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for CareDx’s current-year earnings implies a 25.5% increase from the year-ago reported figure. The consensus mark for its current-year revenues is pegged at $374.08 million. CDNA beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 76.5%.
The Zacks Consensus Estimate for Encompass Health’s 2025 earnings indicates a 19.6% year-over-year increase to $5.30 per share. It has witnessed one upward estimate revision over the past 60 days against no movement in the opposite direction. The consensus mark for EHC’s 2025 revenues indicates 10.4% growth from a year ago.
The Zacks Consensus Estimate for Ensign’s 2025 bottom line suggests 18.2% year-over-year growth. It beat earnings estimates in all the last four quarters, with an average surprise of 2.3%. ENSG has witnessed three upward estimate revisions over the past 60 days against no movement in the opposite direction.